Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AnnexonANNX +2.94%34 EV-to-EBITDA is -3.26 as of Aug. 04, 2026. GuruFocus rates ANNX with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 415 Biotechnology companies, Annexon ranks worse than 240963.61% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Annexon's enterprise value is $660.58 Mil.
Annexon's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-202.69 Mil. Therefore, Annexon's EV-to-EBITDA for today is -3.26.
The historical rank and industry rank for Annexon's EV-to-EBITDA or its related term are showing as below:
ANNX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.27 Med: 0 Max: 0
Current: -3.26
ANNX's EV-to-EBITDA is ranked worse than 100% of 415
companies
in the Biotechnology industry
Industry Median: 11.92
vs ANNX: -3.26
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Annexon's share price for today is $5.25.
Annexon's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.220.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Annexon's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Annexon's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Annexon EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Annexon's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Annexon's EV-to-EBITDA falls into.
Annexon's current Enterprise Value is $660.58 Mil.
Annexon's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-202.69 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Annexon (ANNX) has a EV-to-EBITDA of -3.26 as of Aug. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Annexon. According to the industry distribution chart, Annexon ranks #999999 out of 415 companies in the Biotechnology industry.
Is Annexon's EV-to-EBITDA too high?
Annexon's current EV-to-EBITDA is -3.26. Based on the distribution chart, Annexon ranks #999999 out of 415 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Annexon has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Annexon's EV-to-EBITDA compare to ABUS and TBPH?
According to the Biotechnology industry distribution chart, Annexon ranks #999999 out of 415 companies for EV-to-EBITDA. This places Annexon in the lower half of its industry. The industry median EV-to-EBITDA is 11.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.92, based on 415 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Annexon. For the Biotechnology industry, the median EV-to-EBITDA is 11.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Annexon's current EV-to-EBITDA is -3.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annexon stock overvalued right now?
Annexon (ANNX) has a current EV-to-EBITDA of -3.26. The current EV-to-EBITDA is -3.26. Annexon's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Annexon (ANNX), the current EV-to-EBITDA is -3.26 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
34GF Score
Get the complete analysis for ANNX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANNX has been successfully added to your 
